Skip to main content

Table 1 Patients characteristics

From: Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience

Variable

Whole cohort N (%)

RAI ablation N (%)

Without RAI ablation N (%)

P value*

 Total patients

326/1192 (27.4 %)

182/326 (55.8)

144/326 (44.2)

0.06

Age (years)

42.6 (18–76) SD ±11.6

43.2 (18–76) SD ± 12.4

41.8 (19–71) SD ± 10.2

 

  ≤45 years

201 (61.7)

110 (60.4)

94 (65.3)

0.81

  ≥45 years

125 (38.3)

72 (39.6)

50 (34.7)

 

Gender

  Female

271 (83.1)

146 (80.2)

125 (86.8)

0.06

  Male

55 (16.9)

36 (19.8)

19 (13.2)

 

 Female to male ratio

4.9

4.0

6.5

 

Type of surgery

 Total thyroidectomy

299 (91.7)

182 (100)

117 (81.3)

0.04

 Hemi-thyroidectomy

27 (8.3)

-

27 (18.7)

 

Lymph node surgery

 Central neck dissection

88 (27.0)

54 (29.7)

34 (23.6)

 

 Lateral neck dissection

18 (5.5)

9 (4.9)

9 (6.3)

0.9

 Sampling

55 (16.9)

25 (13.7)

30 (20.8)

 

 None

165 (50.6)

94 (51.7)

71 (49.3)

 

Mean size (cm)

0.61 (0.1–1.0) ± 0.24

0.72 (0.2–1.0) ± 0.21

0.44 (0.1–0.9) ± 0.2

 

  ≤0.5 cm

161 (49.4)

50 (27.5)

111 (77.1)

<0.0001

  ≥0.5 cm

165 (50.6)

132 (72.5)

33 (22.9)

 

Histopathologic variants

  Classic

265 (81.3)

143 (78.6)

122 (84.7)

 

  Follicular

41 (12.6)

21 (11.5)

20 (13.9)

 

  Hurthle cell

8 (2.5)

6 (3.3)

2 (1.4)

 

  Tall cell

11 (3.4)

11 (6.0)

-

0.001

  Sclerosing

1 (0.3)

1 (0.5)

-

 

Multifocal

  Yes

125 (38.3)

122 (67.1)

3 (2.1)

<0.0001

  No

201 (61.7)

60 (32.9)

141 (97.9)

 

ETE

  Yes

62 (19.0)

57 (31.3)

5 (3.5)

<0.0001

  No

264 (81.0)

125 (68.7)

139 (96.5)

 

LVSI

  Yes

55 (16.9)

49 (26.9)

6 (4.2)

<0.0001

  No

271 (83.1)

133 (73.1)

138 (95.8)

 

Surgical margins

  Positive

35 (10.7)

30 (16.5)

5 (3.5)

<0.0001

  Negative

291 (89.3)

152 (83.5)

139 (96.5)

 

Lymph node metastasis

  Yes

42 (12.9)

42 (23.1)

-

<0.0001

  N1a

34 (73.8)

34 (73.8)

  

  N1b

8 (19.2)

8 (19.2)

  

  No

284 (87.1)

140 (76.9)

144 (100)

 

Background thyroid tissue

 Normal

98 (30.1)

47 (25.8)

51 (35.4)

 

 Multi-nodular goiter

106 (32.5)

60 (32.9)

46 (31.9)

 

 Lymphocytic thyroiditis/Hashimotos’ thyroiditis

122 (37.5)

75 (41.3)

47 (32.6)

0.052

Distant Metastasis at presentation

3 (0.9)

3 (1.65)

-

<0.0001

AJCC staging

  I

217 (66.5)

73 (40.1)

139 (96.5)

 

  II

-

-

-

 

  III

96 (29.5)

96 (52.6)

5 (3.5)

<0.0001

  IVA

10 (3.1)

10 (5.6)

-

 

  IVB

-

-

-

 

  IVC

3 (0.9)

3 (1.7)

-

 

Mean postoperative TG (ng/ml)

1.39 (0.1–42890)

2.44 (0.1–42890)

0.39 (0.1–8.9)

0.62

RAI dose

  30 mCi

 

50 (27.5)

-

<0.0001

  100 mCi

 

85 (46.7)

-

 

  150-200 mCi

 

47 (25.8)

-

 

RT to Neck

2 (0.61)

2 (1.1)

-

<0.0001

Recurrences

    

 Locoregional

13 (3.9)

4 (2.2)

9 (6.2)

<0.001

 Distant

10 (3.1)

4 (2.2)

6 (4.2)

 
  1. *P value pertaining to the variation in clinicopathological characteristics between two groups
  2. RAI radioactive iodine 131, N number, SD standard deviation, ETE extra-thyroidal extension, LVSI lymphovascular space invasion, AJCC American joint committee on cancer, TG thyroglobulin, mCi millicurie, RT radiation therapy